Clinical trial · Interventional
Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status
NCT03014973CI-TRIAL-00034842HORMwithdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of the study is to determine the intra-prostatic concentration of sexual steroids when castration resistance appears in castration-resistant prostate cancer patients compared to patients naif of hormonal treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intra-prostatic concentration of sexual steroids | Biological | — | UNRESOLVED |
| Trans-rectal biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- prostate cancer patients resistant to castration
- interventionNames
- Biological: intra-prostatic concentration of sexual steroids
- Procedure: Trans-rectal biopsy
- type
- EXPERIMENTAL
- label
- patients naif of hormonal treatment
- interventionNames
- Biological: intra-prostatic concentration of sexual steroids
- Procedure: Trans-rectal biopsy
Primary outcomes (1)
- measure
- intra-prostatic concentration of sexual steroids
- timeFrame
- 2 weeks
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * group 1: patients with a locally advanced prostate cancer naif of any hormonal treatment * group 2: Patients with a castration-resistant prostate cancer resisting defined by a biological progression * group 2a: without radiotherapy * group 2b: with radiotherapy * Affiliated to a social security scheme * Having given a written consent. Exclusion Criteria: * Patient unable to supply a written consent (patient not understanding French, under guardianship patient). * neuro-endocrine form or sarcomatoid form prostate cancer
References
Publications (0)
Data not yet available
No reference posted for this study.